Posts Tagged ‘preschool depression’

How kids are getting hooked on pills for life

Monday, October 22nd, 2012

Young children were once expected to outgrow their issues; now they’re diagnosed with lifelong psychiatric problems.

Evelyn Pringle & Martha Rosenberg
Alternet – October 2012

© Zurijeta/Shutterstock.com

Where do parents and teachers get the idea there’s something wrong with kids that only an expensive drug can fix? From Big Pharma’s seamless web of ads, subsidized doctors, journals, medical courses and conferences, paid “patient” groups, phony public services messages and reporters willing to serve as stenographers.

Free stenography for Pharma from sympathetic media includes articles like “One in 40 Infants Experience Baby Blues, Doctors Say,” on ABC News and “Preschool Depression: The Importance of Early Detection of Depression in Young Children,” on Science Daily.

For many, the face of the drugs-not-hugs message is Harold Koplewicz, author of the pop bestseller It’s Nobody’s Fault, and former head of NYU’s prestigious Child Study Center. In a 1999 Salon article, Koplewicz reiterated his “no-fault” statement, assuring parents that psychiatric illness is not caused by bad parenting. “It is not that your mother got divorced, or that your father didn’t wipe you the right way,” he said. “It really is DNA roulette: You got blue eyes, blond hair, sometimes a musical ear, but sometimes you get the predisposition for depression.”

Many regard the NYU Child Study Center, which Koplewicz founded and led before leaving in 2009 to start his own facility, as helping to usher in the world of brave new pediatric medicine in which children, toddlers and infants, once expected to outgrow their problems, are now diagnosed with lifelong psychiatric problems. The Child Study Center is “a threat to the health and welfare of children,” and its doctors are “hustlers working to increase their ‘client’ population and their commercial value to psychotropic drug manufacturers,” charged Vera Sharav, president of the watchdog group, Alliance for Human Research Protection.

A look at the center’s stated mission provides no reassurance. Its goal of “eliminating the stigma of being or having a child with a psychiatric disorder,” and “influencing child-related public policy,” sounds a lot like a Pharma sales plan. And its boast about having “a structure that allows recruitment of patients for research studies and then provides ‘real-world’ testing for successful controlled-environment findings,” could send chills down the backs of parents afraid their kids will be guinea pigs or money-making subjects.

In 2007, the fears of the Child Study Center’s skeptics were confirmed when it launched an aggressive, scare tactic marketing campaign called Ransom Notes in 2007. “We have your son,” said one ad, created with bits of disparate type like a ransom note from a kidnapper. “We will make sure he will no longer be able to care for himself or interact socially as long as he lives. This is only the beginning…Autism.”

“We have your daughter. We are forcing her to throw up after every meal she eats. It’s only going to get worse,” said another ad signed “Bulimia.”

“We are in possession of your son. We are making him squirm and fidget until he is a detriment to himself and those around him. Ignore this and your kid will pay,” said another add from “ADHD.” Other ransom ads came from kidnappers named Depression, Asperger’s Syndrome and OCD.

Created pro bono by advertising giant BBDO, the ads were planned to run in New York magazine, Newsweek, Parents, Education Update, Mental Health News and other publications and on 11 billboards and 200 kiosks, according to the press release.

Immediate Outrage

The hostage campaign drew immediate public outrage and more than a dozen advocacy groups joined together in an online petition calling for an end to it. “This is a demonstration of the assaultive tactics used by psychiatry today – in particular, academic psychiatrists and university-based medical centers that are under the influence of their pharmaceutical partners,” Vera Sharav wrote in alerts to AHRP’s mailing list. “If Dr. Koplewicz et al. are not stopped, the campaign will be hitting the rest of the country,” she warned, and informed readers that the campaign was formulated by BBDO, “a major direct to consumer prescription drug advertising firm,” asking the New York State Attorney General’s office to investigate.

Days after the backlash, the center revoked the advertising campaign “after the effort drew a strongly negative reaction,” reported the New York Times. Koplewicz told the Times the decision was made by the center with no pressure from New York University and they planned to introduce a new campaign in the next three months. However, he left the Child Study Center at NYU in 2009 to start his own facility, initially called the Child Study Center Foundation, but changed to the Child Mind Institute, in 2010.

There was more controversy when Koplewicz left the center. When he announced his resignation, New York University “forbade him from entering his office and it pushed out professors who had said they wanted to join him at Child Mind Institute,” reported the New York Times. Twelve NYU professors nevertheless followed Koplewicz to the Child Mind Institute as well as most of the Child Study Center’s influential board of directors, which included Garber Neidich, a chairwoman at the Whitney Museum, the founders of the Tribeca Film Festival founders and some well known financiers. The toxic send-off was followed by the New York State Office of Mental Health firing Koplewicz from his job of nearly four years as director of the Nathan Kline Institute for Psychiatric Research, an affiliate of NYU School of Medicine.

Though Koplewicz’ Child Mind Institute is supposedly a non-profit, it is ensconced on Park Avenue in Manhattan and Koplewicz’ hourly rate “can be as high as $1,000 (three to four times that of the average Manhattan therapist),” says the Times. In a chilling interview on Education Update Online, Koplewicz says the reason his institute works closely with schools “is simply that’s where the kids are” (bringing to mind Willy Sutton, who robbed banks because “that’s where the money is”).

Last month in the Wall Street Journal, Koplewicz wrote that “no studies have examined the effect of long-term use” of ADHD meds, but they “have been in use for 70 years, and there is no evidence that suggests any adverse effects.” But there has been a large federal study of the long-term effects of the drugs and it shows they are “ineffective over longer periods,” and “that long-term use of the drugs can stunt children’s growth,” reported the Washington Post. Oops.

Read the rest of the article here http://www.sott.net/article/252567-How-kids-are-getting-hooked-on-pills-for-life

 

« Return to news items


Share

Big Pharma’s Next Big Thing: Antipsychotic Medicines for Preschoolers

Thursday, September 9th, 2010

BNET

By Jim Edwards

Dr. Joan Luby, the preschool depression researcher at the center of a New York Times article that failed to mention her past research was funded by Johnson & Johnson (JNJ), Shire (SHPGY) and AstraZeneca (AZN), is currently testing the antipsychotic Risperdal on autistic children aged 30 months to 5 years old, according to the ClinicalTrials.gov database. Although the study is not funded by Janssen, the unit of J&J that makes Risperdal, it nonetheless typifies a new field of drug research: The use of mood-altering pharmaceuticals on the very, very young.

The NYT piece investigated the development of preschool depression as a diagnosis. Slate, like me, found it surprising that the author did not believe Big Pharma’s interest in the field was relevant. Minyanville thought the same thing. Such research is controversial. In November 2008, the FDA said antipsychotic drugs were over-used in children and that more should be done to discourage doctors from treating unruly kids with powerful drugs.

Luby — who also believes that certain antidepressants may be effective in children, according to this press release — is just one researcher looking at extending the use of antipsychotics to very young kids. Here’s a study on Lithium vs. Risperdal in kids aged 7 and up. And here’s a similar trial on kids aged 6 and up. GlaxoSmithKline (GSK) is currently testing Paxil on 7-year-olds despite that medicine’s well-document propensity to trigger suicides in young patients.

The reason the FDA has warned against use of these drugs in kids is twofold: First, many of these products are not approved for use in children. Risperdal — the product in the Luby study of 30-month olds — is only approved for use in autistic children older than 5; and for schizophrenics older than 13. Eli Lilly (LLY)’s competing antipsychotic Zyprexa is not indicated for anyone below the age of 13.

Read the rest of this article here http://www.bnet.com/blog/drug-business/big-pharma-8217s-next-big-thing-antipsychotic-medicines-for-preschoolers/5624?tag=content;drawer-container

To see what side effects doctors, pharmacists,  health care providers and consumers have reported to the US FDA regarding antipsychotics and antidepressants on children (including 0-1 year olds) search CCHR’s decrypted FDA Medwatch reports here http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

« Return to news items


Share

Meet the Queen of “Preschool Depression” — and Her Drug Company Backers

Monday, August 30th, 2010

by Jim Edwards

BNET August 30, 2010

The NYT Sunday magazine crowned Dr. Joan Luby as the queen of preschool depression this weekend, but failed to mention that Luby has taken cash from Johnson & Johnson (JNJ), Shire (SHPGY) and AstraZeneca (AZN) to study using atypical antipsychotics in young children. The article is significant because of the outsize role that the Times magazine plays in creating and naming new social trends. (Remember when you suddenly figured out that carbs make you fat but fatty meat doesn’t? That was the NYT mag.)

In this case, the phenomenon is depression in children as young as three years old, and the trend is to treat it with drugs such as Risperdal, Zyprexa, Adderall and Seroquel. The article, by Pamela Paul, provides a useful roadmap into how parenting will be medicalized by Big Pharma:

“The idea is very threatening,” says Joan Luby, a professor of child psychiatry  at Washington University School of Medicine, … “In my 20 years of research, it’s been slowly eroding,” Luby says of that resistance. “But some hard-core scientists still brush the idea off as mushy or psychobabble, and laypeople think the idea is ridiculous.”

The “ridiculous” layperson who first pointed out that Luby had written medical journal articles urging the use of antipsychotics on preschool children without declaring her drug company payments was me. Luby was a paid speaker for AstraZeneca in 2003-2004 (AZ makes Seroquel); she received $2019 in a for a consultancy from Shire in 2004 (Shire makes Adderall and Vyvanse); and prior to 2006 she received grant/research support from Janssen, the unit of J&J that markets Risperdal. Luby is also a member of a group of scientists who want greater study of potential new uses for psychiatric drugs in young children. That group has ties to 16 different drug companies. Some of these drugs have dangerous side effects.

The Archives of General Psychiatry (published by the American Medical Association) said it would investigate how Luby failed to disclose her past ties when it published “Preschool Depression,” a study she did on 3- to 6-year-olds. Joseph Coyle, the editor of the AGP, did not immediately respond to an email requesting an update on its Luby probe. (The American Psychiatric Association, which publishes the American Journal of Psychiatry, has chosen to ignore the issue.)

Read the rest of this article here:  http://www.bnet.com/blog/drug-business/meet-the-queen-of-8220preschool-depression-8221-8212-and-her-drug-company-backers/5595

To read about other pharma funded psychiatrists promoting a psycho/pharma agenda  read Shrinks For Sale – The Corrupt Alliance of the Psychiatric-Pharmaceutical Industry by CCHR   http://www.cchrint.org/cchr-issues/the-corrupt-alliance-of-the-psychiatric-pharmaceutical-industry/

Also read DSM Panel Members Still Getting Pharma Funds by CCHR http://www.cchrint.org/2010/05/21/dsm-panel-members-still-getting-pharma-funds/

« Return to news items


Share

No Surprise: Psychiatrist pushing “Depression” testing for 3-yr-olds connected to three drug companies

Monday, August 17th, 2009

Martha Rosenberg
The Epoch Times
August 17, 2009

Try to access the Web site of the Archives of General Psychiatry, and you may have to abide an ad for the antidepressant Pristiq before you can enter. (JAMA and its Archives Journals “do not endorse the advertised product,” you’ll be assured.)

But look for a pharma affiliation for the author of the article “Preschool Depression,” Joan L. Luby, M.D., in the August issue, and you’ll be told no “financial disclosure” was reported. Not that “Dr. Luby has received grant/research support from Janssen, has given occasional talks sponsored by AstraZeneca, and has served as a consultant for Shire Pharmaceutical,” as a 2006 article in Journal of the American Academy of Child and Adolescent Psychiatry says.

Even though the pharmaceutical industry has 27 million Americans—10 percent of the population—on antidepressants, thanks to direct to consumer advertising, it is looking for depression in preschoolers. And guess what? It’s finding it!

Read entire article: http://www.theepochtimes.com/n2/content/view/21114/

« Return to news items


Share